A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.

Samantha Jaglowski, John C. Byrd, Jennifer A. Woyach et al.|Journal of Clinical Oncology|2012

Cited by 65